An Assessment of the Impact of Disease Activity Criteria on Dosing Interval Assignment in Clinical Trial Patients With nAMD

Related

• 

  Analysis of Retinal Fluid and Vision Outcomes in the Archway Phase 3 Trial of the Port Delivery System With Ranibizumab (PDS) in Patients With nAMD

  Arshad M. Khanani, MD, MA, FASRS

  Annual Meeting Talks

  2021

• 

  Subgroup Analyses From the Phase 3 PULSAR Trial of Aflibercept 8 mg in Patients With Treatment-Naïve Neovascular Age-Related Macular Degeneration

  Keyvan Koushan, MD, FRCSC

  Annual Meeting Talks

  2023

• 

  Expert Panel: AI

  Mark S. Humayun, MD, PhD

  Devinder S Chauhan, MD FRCOphth FRANZCO

  Ursula M. Schmidt-Erfurth, MD

  Jennifer I. Lim, MD, FARVO, FASRS

  Royce WS Chen, MD

  Annual Meeting Talks

  2024